Amneal Pharmaceuticals Inc. presented at the Jefferies Global Healthcare Conference 2025, highlighting a new chapter of growth as a global biopharmaceutical company. The company reported significant diversification and expansion of its portfolio from 2019 to 2024, driving sustainable long-term growth through execution, innovation, and business development. Key areas of focus include expanding in high-growth areas such as GLP-1/Peptides, advancing the biosimilars pipeline, and growing specialty assets like CREXONT® for Parkinson's Disease and Brekiya® for migraine and cluster headache. Financial projections for 2025 indicate an increase in net revenues to $3.0 - $3.1 billion and adjusted EBITDA to $650M - $675M, with a notable reduction in net leverage. You can access the full presentation through the link below.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。